Table Evidence profile table for the impact of delayed treatment due to a false negative on mpMRI compared to biopsy for Population 1 Outcomea Patients/Studies Risk of Inconsistency Indirectness Imprecision Other Result Impact of Importance bias considerations change in (e.g. publication management bias) QoE Overall not Delay did not 41,146 patients not serious serious1 not serious none Critical ⨁⨀⨀⨀ survival serious impact overall VERY LOW (5 studies). survival (results from 5 studies) Cancer free 8,916 patients not not serious serious1 not serious none Delay did not Critical ⨁⨀⨀⨀ impact cancer free survival serious VERY LOW (2 studies). survival (results from 2 studies) Rate of 6,681 patients not not serious serious1 not serious none Delay did not Critical ⨁⨀⨀⨀ metastases serious impact rate of VERY LOW (4 studies). formation metastases formation (results from 4 studies) Biochemical 19,768 patients not not serious serious1 not serious none 3 studies reported Critical ⨁⨀⨀⨀ recurrence serious recurrence was VERY LOW (14 studies). associated with delayed treatment, 11 studies reported no impact. 16,039 patients not not serious serious1 not serious none Delay did not Important ⨁⨀⨀⨀ impact rate of serious VERY LOW (7 studies). extension extension (results from 7 studies) Lymph node 3,605 patients not not serious serious1 not serious none Delay did not Important ⨁⨀⨀⨀ involvement serious impact rates of VERY LOW (3 studies). lymph node involvement (results from 3 studies)
Table Evidence profile table for the impact of delayed treatment due to a false negative on mpMRI compared to biopsy for Population 1 Outcomea Patients/Studies Risk of bias Inconsistency Indirectness Imprecision Other considerations (e.g. publication bias) Result Impact of change in management QoE Importance Overall survival 41,146 patients (5 studies). not serious not serious serious1 not serious none Delay did not impact overall survival (results from 5 studies) ⨁⨀⨀⨀ VERY LOW Critical Cancer free survival 8,916 patients (2 studies). not serious not serious serious1 not serious none Delay did not impact cancer free survival (results from 2 studies) ⨁⨀⨀⨀ VERY LOW Critical Rate of metastases formation 6,681 patients (4 studies). not serious not serious serious1 not serious none Delay did not impact rate of metastases formation (results from 4 studies) ⨁⨀⨀⨀ VERY LOW Critical Biochemical recurrence 19,768 patients (14 studies). not serious not serious serious1 not serious none 3 studies reported recurrence was associated with delayed treatment, 11 studies reported no impact. ⨁⨀⨀⨀ VERY LOW Critical extension 16,039 patients (7 studies). not serious not serious serious1 not serious none Delay did not impact rate of extension (results from 7 studies) ⨁⨀⨀⨀ VERY LOW Important Lymph node involvement 3,605 patients (3 studies). not serious not serious serious1 not serious none Delay did not impact rates of lymph node involvement (results from 3 studies) ⨁⨀⨀⨀ VERY LOW Important